Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FZ-AD004
- Development stage
- Phase 1
- Lead developer
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FZ-AD004 is an investigational antitumor antibody-drug conjugate (ADC) developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical for the treatment of advanced solid tumors. It consists of a monoclonal antibody targeting human trophoblast cell surface glycoprotein antigen (TROP2), conjugated to a cytotoxic payload via the BB05 platform. The payload acts as a DNA topoisomerase I inhibitor and is released in lysosomes after internalization into tumor cells, leading to tumor cell death. The drug is being evaluated in Phase I clinical trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced or metastatic solid tumors. Indications under investigation include lung cancer, breast cancer, gastric cancer, esophageal cancer, colorectal cancer, urothelial cancer, bladder cancer and endometrial cancer[1][2][4][5].
- Other names
- Trop2-BB05 ADCTrop-2-BB05 ADCTrop 2-BB05 ADC
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on FZ-AD004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FZ-AD004.